BACKGROUND: There is a relatively steep dose-response curve for effects of inhaled corticosteroids on conventional airway markers of asthmatic disease control. OBJECTIVE: We sought to determine whether a dose-response effect exists for bronchial hyperresponsiveness. METHODS: A meta-analysis of placebo-controlled trials in asthmatic patients was performed using a computerized systematic review of databases. Doubling dose/dilution protection of inhaled corticosteroid was compared with placebo. Studies which used direct (methacholine and histamine) and indirect (adenosine monophosphate) bronchial challenge stimuli were eligible for inclusion. RESULTS: Twenty-five studies fulfilled eligibility criteria (963 patients). Values for doubling dose/dilution protection categorized by low/medium dose (< 1,000 microg) and high dose (> or = 1,000 microg) of inhaled corticosteroid amounted to a 1.25 (95% confidence interval 1.08 to 1.42) and 2.16 (95% confidence interval 1.88 to 2.44) shift, respectively. CONCLUSIONS: High doses of inhaled corticosteroids conferred greater improvements in bronchial hyperresponsiveness than low doses.
BACKGROUND: There is a relatively steep dose-response curve for effects of inhaled corticosteroids on conventional airway markers of asthmatic disease control. OBJECTIVE: We sought to determine whether a dose-response effect exists for bronchial hyperresponsiveness. METHODS: A meta-analysis of placebo-controlled trials in asthmatic patients was performed using a computerized systematic review of databases. Doubling dose/dilution protection of inhaled corticosteroid was compared with placebo. Studies which used direct (methacholine and histamine) and indirect (adenosine monophosphate) bronchial challenge stimuli were eligible for inclusion. RESULTS: Twenty-five studies fulfilled eligibility criteria (963 patients). Values for doubling dose/dilution protection categorized by low/medium dose (< 1,000 microg) and high dose (> or = 1,000 microg) of inhaled corticosteroid amounted to a 1.25 (95% confidence interval 1.08 to 1.42) and 2.16 (95% confidence interval 1.88 to 2.44) shift, respectively. CONCLUSIONS: High doses of inhaled corticosteroids conferred greater improvements in bronchial hyperresponsiveness than low doses.
Authors: Kaharu Sumino; Elizabeth A Sugar; Charles G Irvin; David A Kaminsky; Dave Shade; Christine Y Wei; Janet T Holbrook; Robert A Wise; Mario Castro Journal: Ann Allergy Asthma Immunol Date: 2014-02-05 Impact factor: 6.347
Authors: S S An; T R Bai; J H T Bates; J L Black; R H Brown; V Brusasco; P Chitano; L Deng; M Dowell; D H Eidelman; B Fabry; N J Fairbank; L E Ford; J J Fredberg; W T Gerthoffer; S H Gilbert; R Gosens; S J Gunst; A J Halayko; R H Ingram; C G Irvin; A L James; L J Janssen; G G King; D A Knight; A M Lauzon; O J Lakser; M S Ludwig; K R Lutchen; G N Maksym; J G Martin; T Mauad; B E McParland; S M Mijailovich; H W Mitchell; R W Mitchell; W Mitzner; T M Murphy; P D Paré; R Pellegrino; M J Sanderson; R R Schellenberg; C Y Seow; P S P Silveira; P G Smith; J Solway; N L Stephens; P J Sterk; A G Stewart; D D Tang; R S Tepper; T Tran; L Wang Journal: Eur Respir J Date: 2007-05 Impact factor: 16.671
Authors: Graeme P Currie; Caroline E Bates; Daniel K C Lee; Catherine M Jackson; Brian J Lipworth Journal: Eur J Clin Pharmacol Date: 2003-03-22 Impact factor: 2.953
Authors: Bruno Sposato; Marco Scalese; Maria Giovanna Migliorini; Maria Piera Riccardi; Massimo Tosti Balducci; Luigi Petruzzelli; Raffaele Scala Journal: Multidiscip Respir Med Date: 2013-09-12
Authors: Aneta Tomkowicz; Maria Kraus-Filarska; Julia Bar; Jerzy Rabczyński; Michał Jeleń; Paweł Piesiak; Andrzej Fal; Bernard Panaszek Journal: Arch Immunol Ther Exp (Warsz) Date: 2008-12-01 Impact factor: 4.291
Authors: Bruno Sposato; Marco Scalese; Nicola Scichilone; Andrea Pammolli; Massimo Tosti Balducci; Maria Giovanna Migliorini; Raffaele Scala Journal: Multidiscip Respir Med Date: 2012-11-17